M
Mary O'Brien
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 358
Citations - 24190
Mary O'Brien is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 62, co-authored 331 publications receiving 19962 citations. Previous affiliations of Mary O'Brien include Maidstone Hospital & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
Mary O'Brien,Nely Wigler,Moshe Inbar,R. Rosso,E. Grischke,Armando Santoro,Raphael Catane,D. G. Kieback,Piotr Tomczak,Stephen P. Ackland,F. Orlandi,L. Mellars,L. Alland,C. Tendler +13 more
TL;DR: In first-line therapy for MBC, PLD provides comparable efficacy to doxorubicin, with significantly reduced cardiotoxicity, myelosuppression, vomiting and alopecia.
Journal ArticleDOI
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csoszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Kristel Vandormael,Antonio Riccio,J. Yang,M. Catherine Pietanza,Julie R. Brahmer +17 more
TL;DR: With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolezumab as subsequent therapy.
Journal ArticleDOI
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Andrew Webb,David Cunningham,J H Scarffe,Peter Harper,A. R. Norman,Johnathan Joffe,M. L. Hughes,Janine Mansi,Michael Findlay,A Hill,Jacqui Oates,Marianne Nicolson,Tamas Hickish,Mary O'Brien,T. Iveson,Maggie Watson,Craig Underhill,Andrew M Wardley,M Meehan +18 more
TL;DR: The ECF regimen results in a survival and response advantage, tolerable toxicity, better QL and cost-effectiveness compared with FAMTX chemotherapy, and should now be considered the standard treatment for advanced esophagogastric cancer.
Journal ArticleDOI
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
Tom Treasure,Loic Lang-Lazdunski,David A. Waller,Judith M Bliss,Carol Tan,James Entwisle,Michael Snee,Mary O'Brien,G. Thomas,Suresh Senan,Kenneth J. O'Byrne,Lucy Kilburn,James Spicer,David Landau,John G. Edwards,Gill Coombes,Liz Darlison,Julian Peto +17 more
TL;DR: The data suggest that radical surgery in the form of EPP within trimodal therapy offers no benefit and possibly harms patients and a larger study is not feasible.